Login / Signup

ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer.

Daniela ZaniniLeandro Henrique ManfrediLuana Paula PelinsonVictor Camera PimentelAndréia Machado CardosoViviane do Carmo Araújo GonçalvesCláudia Bertoncelli Dos SantosJessié Martins GutierresVera Maria MorschDaniela Bitencourt Rosa LealMaria Rosa Chitolina Schetinger
Published in: Medical oncology (Northwood, London, England) (2019)
Cigarette smoking is directly associated with lung cancer. Non-small cell lung carcinoma (NSCLC) represents approximately 80% from all types of lung cancer. This latter is hard to diagnose and to treat due to the lack of symptoms in early stages of the disease. The aim of this study was to evaluate ADA activity and the expression of P2X7, A1, and A2A receptors and in lymphocytes. In addition, the profile of pro-inflammatory and anti-inflammatory cytokines serum levels of patients with lung cancer in advanced stage was evaluated. Patients (n = 13) previously treated for lung cancer at stage IV (UICC) with chemotherapy had their blood collected. Cancer patients showed a decrease in ADA activity and an increase in A1 receptor expression in lymphocytes when compared to the control group. Moreover, patients exhibited an increase in IL-6 and TNF-α, while IL-17 and INF-ϒ serum levels were lower in patients with lung cancer. The decreased ADA activity and the increase in A1 receptor expression may contribute to adenosine pro-tumor effects by increasing IL-6 and TNF-α and decreasing IL-17 and INF-γ serum levels. Our data show an indirect evidence that purinergic signaling may have a role in promoting a profile of cytokines levels that favors tumor progression.
Keyphrases